ArticleNanomaterials (Basel, Switzerland)2022
LDH-TiO
Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 16 citations in OpenAlex.
- High-capacity removal of crystal violet using ZIF-8/graphene quantum dot composite with RSM optimization and explainable machine learning.Scientific reports · 2026Article
- Aqueous Pb(II) Removal Using ZIF-60: Adsorption Studies, Response Surface Methodology and Machine Learning Predictions.Nanomaterials (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Selenium as a nutrient has a narrow margin between safe and toxic limits. Hence, wastewater discharges from selenium-containing sources require appropriate treatment that considers health concerns and stringent selenium-related water treatment standards. This work examined the use of a photocatalysis-cum-adsorption system based on a layered double hydroxide coupled with TiO2 (LDH-TiO2) to remove aqueous phase selenocyanate (SeCN−), which is difficult to treat and requires specific treatment procedures. The synthesized LDH and LDH-TiO2 composite samples were characterized using the X-ray diffraction (XRD), field emission scanning electron microscopy (FESEM), and thermogravimetry analysis (TGA) methods. The XRD results for the uncalcined LDH indicated a hydrotalcite mass with a rhombohedral structure, whereas increasing the calcination temperature indicated transition to an amorphous state. FESEM results for the LDH-TiO2 matrix indicated round titanium dioxide particles and LDH hexagonal layers. The TGA findings for uncalcined LDH showed a gradual decrease in weight up to 250 °C, followed by a short plateau and then a sharp decrease in LDH weight from 320 °C, with a net weight loss around 47%. Based on the characterization and initial selenocyanate adsorption results, the 250 °C calcined LDH-TiO2 matrix was used for the selenocyanate photocatalysis. A ~100% selenium removal was observed using LDH:TiO2 at a 1.5:1 w/w ratio with a 2 g/L dose, whereas up to 80% selenium removal was noted for LDH:TiO2 at a 0.5:1 w/w ratio. The respective difference in the efficiency of selenium treatment was attributed to enhanced LDH-based adsorption sites in the enhanced LDH:TiO2 w/w ratio. Furthermore, the selenite and selenate that occurred during SeCN− photocatalytic degradation (PCD) were also nearly completely removed via adsorption. An optimization exercise using response surface methodology (RSM) for total selenium removal showed R2 values of more than 0.95, with a prediction accuracy of more than 90%. In summary, the present findings show that the use of a photocatalysis-cum-adsorption system based on LDH-TiO2 is a promising technique to treat industrial wastewater discharges for selenocyanate and also remove the resulting intermediates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.